Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Gemmy Cheung, EURETINA 2021: New Insight on Polypoidal Choroidal Vasculopathy

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 17th 2021

We were delighted to speak with Gemmy Cheung (Singapore National Eye Center, Singapore) about recent research in the pathogenesis of polypoidal choroidal vasculopathy, and the gaps in knowledge that remain.

Questions

  1. Could you give us a brief overview of the epidemiology and clinical features of polypoidal choroidal vasculopathy (PCV)? (00:10)
  2. What has recent research taught us about the pathogenesis of PCV? (01:33)
  3. What are the unmet needs in the treatment of PCV and what future studies are planned? (02:54)

 

Speaker Disclosure: Gemmy Cheung has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of EURETINA 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup